Another vote of no-confidence in co-stimulated bispecifics
BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.
FDA green and red lights: July 2024
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
Aegean in the clear
But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.
An unfamiliar name goes after familiar targets
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
ESMO 2024 preview – Summit and BioNTech battle again
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
FDA green and red lights: June 2024
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
IO Biotech looks for an interim injection
The group plays down upcoming interim analysis, but still hopes for accelerated approval.
We haven't lost focus, BioNTech insists
The company defends its cancer strategy, and says it's not a me-too developer.
